Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERLINK-1: Monalizumab or placebo plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor
jRCT2031200161Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Monalizumab + cetuximab with Placebo + cetuximab (2 arms). Primary endpoint: Overall Survival (HPV-unrelated analysis set). Started Oct 2020; status: active, not recruiting.
02
Drugs
monalizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031200161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200161.